CURRICULUM VITAE

SIGNATURE:		**DATE:**	
NAME: **TITLE:**	Scott L. Brown, M.D., F.A.C.S. Principal Investigator	**DATE UPDATED:**	August 2020

RESEARCH SITE ADDRESS & PHONE:

Main Office: TriWest Research Associates, LLC 300 South Pierce St. Suite 201 El Cajon, CA 92020 **Contact Info:** Office: (619) 334-4735 Fax: (619) 334-4769 Email: Drbrown@triwestresearch.com	**Site Number II:** TriWest Research Associates, LLC 8881 Fletcher Parkway, Suite 250 La Mesa, CA 91942 **Contact Info:** Office: (619) 334-4735 Fax: (619) 334-4769 Email: Drbrown@triwestresearch.com

EDUCATION/TRAINING:

INSTITUTION AND LOCATION	DEGREE *(if applicable)*	YEAR(s)	FIELD OF STUDY
Virginia Mason Medical Center Seattle, Washington	Fellowship	1999-2000	Urology
Case Western Reserve University Cleveland, Ohio	Residency	1995-1999	Urology
General Surgery, Case Western Reserve University New York, New York	Residency	2000-2003	Internal Medicine
UHS/The Chicago Medical School North Chicago, Illinois	M.D.	1993	Medical
University of Miami Coral Gables, Florida	B.S.	1987	Chemistry

BOARD CERTIFIED:

BOARD CERTIFIED/ELIGIBLE	YEAR(s)	SPECIALTY
American Board of Urology	2002	Urology
Medical Board of California	2000	Physician & Surgeon

POSITIONS AND EMPLOYMENT:

2020-Present	Principal Investigator, TriWest Research Associates LLC, El Cajon, CA
2004-Present	Physician, San Diego Urology Associates, La Mesa, CA
2000-2003	Physician, San Diego Center for Urology, La Mesa, CA
2000-2002	Investigator, San Diego Urology Center-Research Division, La Mesa, CA
2002-2004	Investigator, Center for Urological Research, La Mesa, CA

RESEARCH EXPERIENCE:

Scientific Research:

1997 - 1998	Case Western Reserve University Department: Urology Project: Testicular Torsion and pH Changes in A Rat Model
1992	UHS/The Chicago Medical School Department: Urology Project: Methodology to Change Semen and Urinary pH in Men with Prostatitis
1987	University of Miami School of Medicine Department: Psychology Project: Hypertension in Minority Groups
1986 – 1987	University of Miami Department: Chemistry Project: Extraction and Identification of Volatile Substance From Citrus Fruits
1986 – 1987	University of Miami Department: Anthropology Project: The Relationship of Athletic Injuries to Playing Surfaces

Clinical Research:

Protocol CAPSS-101: Phase 3B A Multi-Center, Double-Blind Study to Compare the Safety and Efficacy of XXXX to that of XXXX in the Treatment of Chronic Prostatitis.

Protocol M98-946: A 12-Week Safety and Efficacy Study of Oral Study Medication Versus Placebo in Subjects with Overactive Bladder.

Protocol 9393IL/0028: A Randomized Clinical Trial Comparing XXXX 3.6 mg Depot and XXXXX 10.8 mg Depot in Subjects with Prostate Cancer for Whom Therapy is Indicated.

Protocol UMD-00-067: Satisfaction and Experience with Testosterone Replacement Therapy.

Protocol DMFO 0341-A2: Phase III Randomized, Double-Blind Study of XXXX vs. Placebo in Low Grade Superficial Bladder Cancer.

Protocol AGL 9909: A Six-Month, Open Label, Fixed Dose Study to Evaluate the Safety, Tolerance, Pharmacokinetics and Endocrine Efficacy of Two Doses of XXXX 22.5 mg In Patients with Advanced Prostate Cancer.

Protocol M97-786: Randomized Prospective Study of Adjuvant Androgen Ablation in Radical Prostatectomy Patients at High Risk for Disease Recurrence.

Protocol 905-CL-013: A Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Fixed-Dose, Multi-Center Study to Assess Efficacy and Safety of Daily Oral Administration of Study Medication vs Placebo in Male and Female Subjects with Overactive Bladder.

Protocol AGL0001: An Eight Month, Open-Label, Fixed Dose Study to Evaluate the Safety, Tolerance, Pharmacokinetics and Endocrine Efficacy of Two Doses of XXXX 30mg in Patients with Advanced Prostate Cancer.

Protocol Alfaurus EFC4428: A Double-Blind Randomized Parallel Group Study of XXXX 10 mg QD versus Placebo in the Management of Acute Urinary Retention in Patients with a First Episode Due to BPH.

Protocol Altess EFC4485: Long-Term, Efficacy and Safety of XXXX10 mg OD on the Risk of Acute Urinary Retention and the Need for Surgery in Patients with BPH.

Protocol: Open Label Use of a Unique Testosterone Topical Gel Formulation in Males with and Original Baseline Testosterone Level < 300ng/dl

Protocol MOO-258: A Phase III, Extension Study to Evaluate Safety of XXXX in Men with Hormone Refractory Prostate Cancer.

Protocol YM905-CL-016: An Open-Label, Long-term Tolerability Study of Daily Oral Administration of 10 mg XXXX in Male and Female Subjects with Overactive Bladder.

Protocol MOO-244: A Phase III, Randomized, Double Blind, Placebo Controlled Study of the safety and efficacy of 10 mg XXXX in Men with Non-Metastatic, Hormone-Refractory Prostate Cancer.

Protocol SB223412/020: A Four-Week “Proof of Concept” Study to Determine the Safety, Tolerability and Efficacy of XXXX in Patients with Symptoms of Urinary Urgency with or without Incontinence.

Protocol MOO-211: A Phase III, Randomized, Double Blind, Placebo Controlled Study of the safety and efficacy of 10 mg XXXX in Men with Metastatic, Hormone-Refractory Prostate Cancer.

Protocol SDUC001: Plasma Isolation Study-FastPack™ PSA Immunoassay.

Protocol A1371047-1221: A Phase 3B, Multi-Center, Double Blind, Randomized, Placebo Controlled, Parallel Group Study of XXXX in Subjects with Overactive Bladder.

Protocol MO1-366: A Phase II Study, Evaluating the safety and efficacy of XXXX in Men with Hormone Naïve Prostate Cancer that are Exhibiting Early Signs of Biochemical Failure.

Protocol MOO-234: Validation Study of The Abbott Urinary Symptom Questionnaire (AUSQ) for Urinary Incontinence and The Overactive Bladder.

Protocol CZOL446E US24: An Open Label Trial on the Effect of I.V. XXXX 4mg on Bone Mineral Density in Hormone Sensitive Prostate Cancer Patients.

Protocol SB-782528: A twelve week flexible dose regimen of XXXX compared to placebo in male erectile dysfunction subjects of broad etiology previously unresponsive to Viagra therapy by history.

Protocol SP668: Phase II Overactive Bladder study to investigate the safety of three different doses of sustained release XXXX in subjects with overactive bladder showing either involuntary detrusor contractions or normal findings during baseline urodynamic assessment.

Protocol A1371042: A Long-Term, Open-Label, Multi-Center Study of XXXX in Subjects with Over-Active Bladder.

Protocol ARIA4006: A Randomized, Double-Blind, Placebo Controlled, Parallel Group of Study of Efficacy, and Safety of XXXX 0.5 mg Administered Once Daily for Four Years to Reduce the incidence of Biopsy-Detected Prostate Cancer.

Protocol C02-008: Phase III, Open-Label, Single Dosage, Uncontrolled, Multi-center Study Conducted in Men with Prostatic Adenocarcinoma. Two doses of 45mg XXXX given 26 weeks apart.

Protocol 10621: A Randomized Double-Blind, Four Month Study to Compare the Tolerability and Efficacy of Flexible Dose XXXX versus Placebo in Men with Depression and Erectile Dysfunction.

Protocol MedTap Pharmacueticals: Questionnaire Study for Patients with Over-Active Bladder including Presence of Urinary Urgency with or without Urinary Incontinence.